Anthera Pharmaceuticals Inc (NASDAQ: ANTH) is having an overwhelmingly strong day in the market, seeing massive gains as traders get excited. The gains started just after the stock got into oversold territory as traders sent the stock skyrocketing to the top. However, is there something to this one that traders are onto? Today, we’ll talk about:
- The value proposition surrounding ANTH;
- what we’re seeing from the stock; and
- what we’ll be watching for ahead.
The Value Proposition Surrounding ANTH
As mentioned above, Anthera Pharmaceuticals is flying in the market after reaching oversold territory. With the massive gains, many are wondering if the traders are onto something here or if the stock is destined to fall back to the bottom. Digging into the value proposition offered by ANTH brings up some concern.
First and foremost, the company was in the process of developing two treatments. Those treatments are known as Blisibimod and Sollpura. Unfortunately however, Blisibimod is the only real asset the company has left. On March 12, ANTH reported top-line results from a clinical study surrounding Sollpura as a treatment for EPI due to cystic fibrosis. While the secondary endpoint was met the study did not meet its primary endpoint, scratching this potential treatment out of the pipeline.
This leaves Blisibimod. Currently, ANTH is in the midst of Phase 2 trials surrounding this drug as an option for the treatment of IgAN. While the data was relatively positive in the middle of the study, investors are still awaiting the full trial results. In the most recent interim analysis, data was offered at the 48 week point. In the release, the company said that a positive trend on proteinuria by blisibimod was observed. Considering the strong results, the company may have something good here, but that is yet to be seen until the results become available.
What We’re Seeing From The Stock
With the stock reaching oversold territory recently, it only makes sense that we’re seeing a reaction among traders that are looking to take advantage of the trends. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:17), ANTH is trading at $0.39 per share after a gain of $0.099 per share or 33.99% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
While Anthera is running up in the market today, the gains are ultimately the result of traders trading. At the moment, the company is crippled due to its recent loss of a pipeline product. However, should coming Phase 2 data be positive, the game could change in a big and very positive way. Nonetheless, we’ll continue to keep a close eye on the news and bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!